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1. CHAPTER 1 
1.1 Introduction 
Tuberculosis (TB) remains the leading cause of death from a single infectious agent worldwide. 
In 2017, an estimated 10.0 million people developed TB disease of which two thirds belonged 
to eight countries namely India, China, Indonesia, the Philippines, Pakistan, Nigeria, 
Bangladesh and South Africa [1]. Furthermore, multidrug resistant TB (MDR-TB) was 
declared a global health crisis by the World Health Organization (WHO) and continues to pose 
a challenge. MDR-TB is defined as resistance to isoniazid (INH) and rifampicin with or without 
resistance to other anti-TB drugs [2]. An estimated 558,000 people developed TB resistant to 
rifampicin in 2017 of which approximately 82% had MDR-TB [1]. 
1.1.1 Defining the clinical problem  
South Africa continues to feature on the WHO list of top 30 high TB burden countries. 
Additionally, it is one of the top 14 high burden countries with drug-resistant and HIV 
associated TB [1]. This high HIV/TB co-infection rate contributes to the disease burden of 
TB because HIV infected patients frequently present with smear negative TB or 
extrapulmonary TB, which is diagnostically challenging [3, 4]. 
In 2016, the WHO released a guideline recommending a shortened MDR-TB treatment 
regimen. When compared to the conventional long regimen this shortened regimen (SR) 
showed a successful patient outcome of 84% (95% CI 79-87) vs 62% (95% CI 53-70). These 
recommendations were based on observational studies from ten countries. The new 
recommendation states that in patients with rifampicin resistant-TB (RR-TB) or MDR-TB who 
were not previously treated with second-line drugs and in whom resistance to fluoroquinolones 
(FQ) and second-line injectable drugs (SLIDs) was excluded or considered highly unlikely, a 
shorter MDR-TB regimen of 9–12 months may be used instead of the longer regimens [5]. 
Rifampicin resistant TB is defined as resistance to at least rifampicin, with or without resistance 
to other drugs [2]. 
Given the high MDR-TB prevalence rate and its associated poor treatment outcomes in South 
Africa, in 2016, the South African National Department of health (NDoH) replaced the existing 
long conventional MDR-TB treatment regimen with the “Modified South African 9-12 Month 
Regimen”. The modified regimen comprised the intensive (injectable) phase; kanamycin + 
moxifloxacin + clofazamine + ethionamide + pyrazinamide + high dose INH + ethambutol for 
4-6 months followed by the continuation phase of moxifloxacin + clofazamine  + pyrazinamide 
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+ ethambutol for a further 5 months. Only patients with RR-TB or MDR-TB (with one INH 
mutation only i.e. either inhA or katG) are eligible for this regimen. Therefore, to facilitate 
rapid triaging of patients on to the SR, there was a growing need to implement rapid molecular 
methods to identify resistance to FQ and SLIDs [6]. 
Alongside the SR recommendation, in 2016, the WHO also released a policy guidance on the 
use of molecular line probe assays (LPA) for the detection of resistance to second line 
antimycobacterial drugs. The policy states, for patients with confirmed RR-TB or MDR-TB, 
the GenoType MTBDRsl Version 2 (Hain Lifescience, Nehran, Germany) may be used as the 
initial test, instead of phenotypic culture based drug susceptibility testing (DST) to detect 
resistance to FQ and SLIDs. The GenoType MTBDRsl Version 2.0 is a qualitative test that 
offers rapid diagnosis of extensively drug resistant TB (XDR-TB) and pre-XDR-TB by 
detecting resistance to FQ and SLIDs on clinical specimens or cultured isolates [7]. Although 
the WHO has endorsed the use of this test for direct testing on smear positive and smear 
negative specimens, a systematic Cochrane review published by Theron et al. highlighted the 
paucity of data on the use of GenoType MTBDRsl Version 2.0 when used directly on smear 
negative specimens. Their analysis has emphasized the need for further evaluation of this assay 
in different geographic settings [8]. 
Considering both WHO guidelines (the use of molecular LPA and the SR), in 2017, NDoH 
implemented a nationwide revised laboratory-clinical algorithm termed Drug Resistant TB 
(DR-TB) Reflex testing in order to facilitate the rapid diagnosis and management of drug 
resistant TB in South Africa. In this algorithm, patients with newly diagnosed RR-TB by 
GeneXpert (GXP) (Cepheid, United States) were commenced on the SR, provided they did not 
have complicated extrapulmonary TB, and resistance FQ and SLIDs was unlikely. In all 
patients, a second sputum specimen was sent to the laboratory for DR-TB Reflex testing. DR-
TB Reflex testing comprises a set of laboratory tests which include, Auramine smear 
microscopy, TB culture on Mycobacteria Growth Indicator Tube (MGIT) 960 system 
(BACTEC MGIT Becton Dickinson, USA), GenoType MTBDRplus (FL-LPA) (Hain 
Lifescience, Nehran, Germany), followed by GenoType MTBDRsl (SL-LPA) sequentially on 
the clinical specimen regardless of smear status [6]. Further DST was performed in selected 
isolates. Once, the results of both LPA’s were available, the SR was either continued or 
adjusted accordingly in the respective patients.  
Since the implementation of DR-TB Reflex testing in the province of KwaZulu-Natal (KZN) 
in January 2017, there have been no published reports on the experience of the routine use of 
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the SL-LPA on clinical specimens within South Africa nor in KZN specifically. In this region, 
smear negative TB remains a significant challenge due to the high rate of HIV associated TB 
(70%). The performance of diagnostic tests in programmatic settings is often inferior compared 
to that in controlled research settings. Given the high burden of drug resistant TB and HIV 
associated TB in KZN; this is an ideal region to assess the feasibility of introducing the SL-
LPA as part of the DR-TB reflex algorithm. The objective is to evaluate the feasibility of the 
routine use of this test in a region were the prevalence of smear negative TB remains high, as 
well as characterize the various mutation patterns detected in this region. This will significantly 
contribute to our knowledge on the routine use of this assay within our population and inform 
further advances when designing molecular tests.  
1.2 Critical Literature Review 
1.2.1 Epidemiology of Tuberculosis 
Despite the TB incidence rate falling at about 2% per year worldwide, according to the 2018 
WHO Global TB Report, TB has still caused an estimated 1,3 million deaths globally [1]. 
Although TB is one of the oldest diseases known, it is still the leading cause of death by a 
single infectious agent and remains amongst the top 10 causes of death. In 2017, 10 million 
people developed active TB disease. Two thirds belonged to eight countries: India (27%), 
China (9%), Indonesia (8%), Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh (4%) 
and South Africa (3%). South Africa remained in the top 30 high burden countries in 2018 with 
an estimated 500 new cases per 100 000 population. Despite WHO declaring MDR-TB a public 
health crisis, drug resistant TB still remains a significant challenge. In 2017, an estimated 
558,000 people developed RR-TB of which approximately 82% had MDR-TB [1]. 
The NDoH conducted the most recent South African national drug resistant prevalence survey 
from 2012 – 2014. In this survey, published by Nazir et al., the prevalence of MDR-TB was 
2,1% (95% CI 1, 5–2,7) among new tuberculosis cases and 4,6% (3,2–6,0) among retreatment 
cases. Amongst MDR-TB patients, 4,9% XDR-TB and 16% had pre-XDR-TB. XDR-TB is 
defined as MDR-TB with resistance to any FQ as well as one or more of the three SLIDs 
(amikacin, kanamycin or capreomycin). Pre-XDR-TB is defined as MDR-TB with additional 
resistance to either a FQ or SLIDs. In this survey, prevalence of MDR-TB varied between all 
9 provinces, however, KZN, had amongst the highest prevalence of patients with MDR-TB, 
showing an overall MDR estimate of 2,9% (95% CI 1,8-4,5) which is higher than the national 
average of 2,8 % [9].  
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Apart from the high burden of MDR-TB, KZN also has the highest burden of XDR-TB. In a 
study published by Kapwata et al., 1027 new XDR TB cases were diagnosed throughout all 11 
districts of KZN during 2011-2014. Using geospatial analysis, they observed that majority of 
XDR-TB was due to primary transmission [10].  
 
1.2.2. Traditional diagnosis and susceptibility testing of TB 
Historically, laboratory diagnosis of TB relied on microscopy using acid fast stains (e.g. Ziehl 
Neelsen) on sputum specimens to detect acid-fast bacilli (AFB). AFB are bacteria that have 
mycolic acids in their cell wall. These mycolic acids do not allow basic dyes e.g. crystal violet 
to penetrate the cell wall and therefore AFB cannot be easily viewed by the Gram staining 
technique. With the Auramine-O staining technique, the fluorochrome dye, Auramine-O, forms 
a complex with the mycolic acids in the cell wall of the organism and makes it resistant to 
decolourisation by acid-alcohol. The counterstain, potassium permanganate, renders 
surrounding tissue and debris non-fluorescent. AFB can then be visualized under the 
fluorescent microscope as bright yellow-green bacilli [11]. 
In South Africa, the traditional method to diagnose pulmonary TB was to submit two early 
morning sputum specimens for smear microscopy. Thereafter, these sputum specimens were 
cultured on liquid or solid media to isolate Mycobacterium tuberculosis (MTB). The 
advantages of AFB microscopy for initial diagnosis included low cost and high specificity in 
areas with a high prevalence of TB [12]. However, a major disadvantage is reduced sensitivity 
when the bacterial load in the specimen is less than 10,000 organisms/ml. The sensitivity is 
also reduced in paediatric patients and in patients with HIV/TB co-infection due to the 
paucibacilliary nature of TB disease in these patients [13]. Some studies have shown a further 
reduction in sensitivity of smear microscopy by approximately 15% in patients with HIV/TB 
co-infection [4]. In an effort to improve the diagnosis of TB by microscopy, in 2011, the WHO 
recommended that conventional fluorescence microscopy be replaced by Light Emitting Diode 
fluorescent microscopy (LED-FM). In a meta-analysis published by Chang et al., LED-FM 
showed a pooled sensitivity of 66,9%  (95% CI 60,5–72,7%) and pooled specificity of 96,8% 
(95% CI 93,1–98,6%). Importantly, the sensitivity was reduced in HIV positive population 
where a pooled sensitivity of 53,0%  (95% CI 42,8–63,0%) and pooled specificity of 96,1% 
(95% CI 86,0–99,0%) was observed [14]. This reduction in sensitivity within the South African 
population, where the HIV/TB co-infection rate remains high gives rise to a further diagnostic 
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challenge. In the South African setting, a considerable number of patients have smear negative 
TB and therefore smear microscopy results may be falsely negative. Due to this high rate of 
false negative smear microscopy results, the WHO still recommends that sputum culture should 
be encouraged as part of the diagnostic workup in HIV infected individuals [15]. In South 
Africa, many patients who are smear negative at baseline are commenced on empiric TB 
treatment whilst awaiting culture confirmation. Empiric TB treatment is defined as the 
administration of TB treatment to persons being evaluated for TB who do not have laboratory 
evidence of TB [3]. 
Culture confirmation of viable TB bacilli using liquid media is currently the gold standard for 
the definitive diagnosis of MTB [16]. Liquid culture is performed in the BACTEC MGIT 960 
TB System. The MGIT consists of modified Middlebrook 7H9 broth base and an enrichment 
supplement, MGIT OADC (oleic acid, albumin, dextrose and catalase). Before inoculation of 
decontaminated specimens into the MGIT tubes, MGIT PANTA is added (polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim and azlocillin) to inhibit contaminating 
organisms. The principle of the detection using the BACTEC MGIT system is based on the 
detection of fluorescence. The MGIT tube has an oxygen-quenched fluorochrome embedded 
in silicone at the bottom of the tube. As bacterial growth occurs, free oxygen inside the tube is 
utilized and replaced by carbon dioxide. When the oxygen is depleted, the fluorochrome is no 
longer inhibited by the oxygen and results in fluorescence within the MGIT when visualized 
under ultraviolet light. The intensity of the fluorescence is directly proportional to the extent 
of oxygen utilization [17]. The major advantage of liquid culture is the shorter time to detection 
(TTD) compared to solid media, as well as improved sensitivity when compared to smear 
microscopy. Studies have shown a TTD of approximately 12 days compared to 23 days in solid 
media [18]. With respect to sensitivity, studies have shown that the limit of detection (LOD) 
for MTB in the BD BACTEC MGIT 960 TB system is approximately 10 to 100 CFU/ml. 
Colony forming units (CFU) is a unit commonly used to estimate the concentration of 
microorganisms in a test specimen [16].  
 DST was originally routinely used to determine the susceptibility pattern of MTB. 
Determining the susceptibility patterns of various antimycobacterial agents is critical in 
prescribing effective drug regimens in patients with confirmed TB. The commonly used 
method for DST is the 1% agar proportion method. In this method, resistance to a drug is 
established when 1% of the total bacterial population display resistance to a specific drug[11]. 
DST can be performed on liquid or solid media. The preferred method in high throughput 
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laboratories in South Africa is liquid media using BACTEC MGIT 960 TB system. The 
principle of this test is that pure cultures of MTB are inoculated in a known concentration of 
drug. Concurrently, the same TB isolate is inoculated as a growth control with no added drug. 
The amount of fluorescence detected in each tube is analysed and reports a “Growth Value”. 
In order to determine the susceptibility of the isolate, the fluorescence in the drug containing 
tube and the drug free tube are compared. If the isolate grows in the control tube and not in the 
drug containing tube, the isolate is reported as susceptible to the tested drug. If the isolate grows 
in both tubes, then it is considered resistant to the tested drug [17].  
 
1.2.3 Molecular basis of drug resistance in TB  
Two well-known resistance mechanisms occur in MTB:  
(i) Primary (transmitted) drug resistance: 
 This mechanism occurs when drug resistant strains are transmitted directly to the host.  
(ii) Secondary (acquired) drug resistance:  
This mechanism occurs in response to inadequate antimycobacterial treatment. Within every 
population of TB bacilli occurring in the lung, there exists bacteria with spontaneously 
occurring mutations. If inadequate treatment is introduced, selection pressure occurs and the 
resistant subpopulations are selected out. As a result acquired resistance develops [19].  
1.2.3.1 Rifampicin 
The target for rifampicin is the β subunit of RNA polymerase which is encoded for by the rpoB 
gene. Majority of rifampicin resistance in MTB is caused by mutations in the rpoB gene. Within 
the rpoB gene, greater than 95% of these mutations occur in the 81 base pair region, which 
extends from codon 507 to 533 according to the E. coli numbering system. This mutation 
hotspot area is termed the rifampicin resistance-determining region (RRDR). Within the RRDR 
codons 526 and 531 are reported to harbour the most common rifampicin mutations. Globally, 
S531L mutations is reported as the most common followed by, H526Y, H526D, and D516V 
[20]. Rifampicin resistance has also been reported to occur outside the RRDR as well. 
Resistance to rifampicin usually accompanies resistance to other drugs, most commonly being 
INH. This makes it an ideal surrogate marker for MDR-TB [21]. 
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1.2.3.2 Isoniazid  
INH is a prodrug that requires activation by the catalase/peroxidase enzyme. The katG gene 
encodes for, this enzyme. Once activated, INH inhibits a mycobacterial protein, InhA. This 
protein is responsible for mycolic acid biosynthesis and encoded for by the inhA gene.  The 
two main mechanisms of resistance to INH are: (i) loss of activation by the katG gene and, (ii) 
increase in expression of inhA gene. The commonest mutation observed is the katG S315T 
mutation. This mutation is associated with high-level INH resistance. Mutations in the inhA 
promoter region results in over expression of inhA gene. This mutation is associated with low-
level resistance to INH and cross-resistance to ethionamide [19, 21].  
1.2.3.3 Fluoroquinolones 
Fluoroquinolones are bactericidal antibiotics that target the DNA gyrase enzyme. This enzyme 
is encoded for by the gyrA and gyrB genes and is essential for DNA replication. Majority of 
fluoroquinolone mutations are found in the quinolone resistance determining region (QRDR), 
which is a highly conserved region within gryA and gyrB genes. The most commonly occurring 
mutations occur at codon 90 and 94 of the gyrA gene. Specifically, A90V, D94G and D94H 
are frequent amongst clinical isolates. Mutations occurring in the gyrB genes are rare [19, 21].  
1.2.3.4 Aminoglycosides (Second line injectable agents) 
The second line injectable agents, kanamycin and amikacin are aminoglycosides and 
capreomycin is a cyclic polypeptide. All three drugs act by binding to the 30S subunit of the 
mycobacterial ribosome, which alters the 16SrRNA structure, resulting in inhibition of protein 
synthesis. The rrs gene encodes for 16SrRNA. Globally, mutations within the rrs gene, 
specifically at position 1401, are common and is associated with high-level aminoglycoside 
resistance. The eis gene encodes for acetyltransferase enzyme. Mutations in this gene are 
associated with low-level kanamycin resistance [19, 21].  
 
1.2.4. Introduction of rapid molecular TB testing in South Africa 
1.2.4.1 GenoType MTBDRplus 
The first genotypic test routinely implemented in a programmatic setting in South Africa was 
the GenoType MTBDRplus Version 1 in the year 2009. In 2008, the WHO endorsed the 
GenoType MTBDRplus assay and recommended that it replace DST for INH and rifampicin 
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in all smear-positive and culture-positive specimens. GenoType MTBDRplus is a line probe 
assay and it is a qualitative test designed for the detection of MTB Complex (MTBC) and its 
resistance to rifampicin and INH. Resistance to rifampicin is detected by looking at the 
mutations in the RRDR region of the rpoB gene and resistance to INH is detected by looking 
at mutations in the katG and inhA promoter regions [22]. The updated version of the assay 
(GenoType MTBDRplus Version 2.0) is intended for use directly on decontaminated smear 
positive and smear negative pulmonary specimens as well as cultured MTB isolates. Reported 
sensitivity and specificity for detection of both rifampicin and INH resistance from cultured 
isolates were 98,1% and 98,7% respectively. However, studies show that estimated reports of 
sensitivity when performed directly on sputum specimens are lower. When performed directly 
on smear positive specimens, studies have shown an approximate sensitivity of 95% but in 
smear negative specimens, reported sensitivities are further reduced to approximately 65% 
[23]. Another study performed in Ethiopia compared the sensitivity of this test when performed 
directly on smear negative and smear positive clinical specimens. They also found a reduced 
sensitivity of 78% in smear negative specimens when compared to the 96,4% sensitivity in 
smear positive specimens [24]. 
The principle of this test is based on DNA–STRIP technology and the procedure is divided into 
3 steps; (i) DNA extraction, (ii) amplification with biotinylated primers, and (iii) reverse 
hybridization. The membrane strips are coated with specific probes that are complementary to 
the amplified MTB nucleic acids present in the specimen. After chemical denaturation, the 
newly generated amplicons binds to the probes on the membrane. Highly specific binding is 
ensured by the buffer composition and specific temperature during hybridization. This binding 
becomes visible as coloured banding patterns when the biotin labelled amplicons bind to 
streptavidin labelled alkaline phosphatase. For interpretation, the banding patterns of gene 
locus controls, WT and MUT are compared to the conjugate and amplification control (see 
template below). The presence of all wild type (WT) bands and no mutation (MUT) bands 
indicate susceptibility. Resistance is reported when there is absence of a WT band with 
presence of a corresponding MUT band (defined mutation), or, the absence of WT bands only, 
without any corresponding MUT band (undefined mutation/resistance inferred). In certain 
isolates, where all WT probes and single or multiple MUT bands develop, these isolates are 
interpreted as resistant and are possibly due to a heteroresistant strains of MTB. The LPA is 
considered uninterpretable (inconclusive) if all bands of a gene locus (including the locus 
control) are missing.  
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Fig.1. GenoType MTBDRplus interpretation 
template. 
 
 
 
 
The main advantage of the GenoType MTBDRplus is the speed at which it offers diagnosis 
and susceptibility testing. Due to the rapid turnaround time of this test, the routine use of this 
assay proved to be beneficial. A study performed in a high throughput TB laboratory in Cape 
Town, South Africa compared traditional liquid culture and DST (using the agar proportion 
method on solid media) to the GenoType MTBDRplus. They found the use of this test reduced 
the time to treatment initiation in patients with MDR-TB from 80 days using conventional 
methods to 55 days by using FL-LPA [25].  
There are several limitations to this assay: 
(i)  It is a procedurally complex test, which requires a special centralised molecular facility and 
highly trained personnel, 
 (ii)  DNA based testing detects viable and non-viable bacteria; therefore, the test cannot be 
used for treatment monitoring,  
(iii) The test only detects mutations that are confined to the RRDR of the rpoB gene, katG and 
inhA promoter regions. Therefore, mutations occurring outside these regions can be missed, 
(iv) It detects silent mutations, which may have questionable clinical significance, 
 (v) Resistance may occur despite the presence of all WT bands. This may be due in the 
presence of a heteroresistant strain where the resistance pattern of the strain is not covered by 
the mutation probes in the assay [26].  
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1.2.4.2 GeneXpert MTB/Rif and GeneXpert MTB/Rif Ultra  
With the persistently high prevalence of TB, HIV associated TB, and drug resistant TB in South 
Africa, it became increasingly important to implement rapid genotypic methods for detection 
of TB and rifampicin resistance at the time of initial patient presentation [27]. Detection of 
MTB using the GenoType MTBDRplus at initial patient presentation was impossible due to 
the several limitations discussed above. The most important limitations being the inability to 
decentralize this test because of its procedural complexity, and the need for a special molecular 
facility. In 2011, following the WHO recommendation for the use of GXP MTB/Rif assay, 
endorsing it as ‘‘the initial diagnostic test in individuals suspected of MDR-TB or HIV 
associated TB’’, the NDoH together with National Health Laboratory Services (NHLS), 
replaced conventional microscopy, culture and DST with the routine use of GXP MTB/Rif 
assay for the initial diagnosis of TB nationwide [28]. The GXP MTB/RIF assay offered a few 
advantages over smear microscopy and the GenoType MTBDRplus. This is largely because of 
its ability to rapidly diagnose MTB and detect rifampicin resistance directly on clinical 
specimens at a decentralized site, using real time polymerase chain reaction (PCR) technology. 
The principle of this real time PCR is based on molecular beacon technology. Molecular beacon 
probes consist of a stem loop structure with the nucleotide sequence embedded within the stem 
loop. There is a fluorescent dye and a quencher at the 5' and 3' end of the structure. In this test, 
five nucleic acid hybridization probes are used to cover the RRDR region of the rpoB gene. If 
a mutation exists in the specimen, the binding of the probe and amplicons is impaired and the 
beacon fails to emit fluorescence. The low limit of detection of 131 CFU/ml contributes to 
higher sensitivity than that of smear microscopy [29]. Laboratory evaluations of the GXP 
MTB/RIF assay showed a sensitivity of 98,3% on smear positive cases [30]. A study by 
Lombardi et al.  found a lower GXP sensitivity of 73,1% for smear-negative culture-confirmed 
TB isolates [31]. 
Although the GXP may have led to more TB diagnoses, the introduction of this molecular 
technique still posed a challenge in our patient population due to its limited sensitivity of 66,1% 
(95%CI  56,4-74,9) in patients with smear negative TB [32]. The GXP MTB/Rif Ultra is an 
improved version of the assay. This updated version includes six nucleic acid probes; two of 
which bind to IS1081 and IS6110 and four probes bind to the RRDR in rpoB gene. Secondly, 
mutations are now determined by the analysis of melting temperatures.  Studies have shown 
improved the sensitivity of this test assay in smear negative TB to 78,9 % (95%CI 70,0-86,1), 
however a considerable gap in sensitivity remains when compared to its performance in smear 
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positive clinical specimens [32]. As a result, the NDoH uses a specific algorithmic approach 
for the use of GXP Ultra in HIV positive patients. In this patient population, a negative GXP 
result cannot adequately rule out TB and a subsequent specimen for culture confirmation of 
viable bacilli must be obtained. Thereafter, if TB was cultured, further molecular testing using 
GenoType MTBDRplus is used for the confirmation of rifampicin and INH susceptibility. 
According to the GXP algorithm, in RR-TB and MDR-TB cases further DST for second line 
drugs is required [33]. 
 
1.2.4.3 GenoType MTBDRsl Version 2 
In 2015, Hain Lifescience released an improved version of the GenoType MTBDRsl LPA 
Version 2. This qualitative test offers rapid detection of pre-XDR and XDR-TB. The SL-LPA 
allows for the identification of MTB and its resistance to FQ and SLIDs directly from smear-
positive and smear negative sputum specimens, as well as cultured isolates. The principle of 
testing is based on DNA-STRIP technology and is similar to the GenoType MTBDRplus. The 
genetic targets included in this assay are gyrA and gyrB for FQ and the rrs and eis promoter 
for SLIDs [34]. The principles of interpretation are the same as for GenoType MTBDRplus 
however with a different template.   
 
 
 
 
Fig.2. GenoType MTBDRsl Version 2 
template.  
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1.2.5 Treatment of drug resistant TB  
1.2.5.1 Conventional treatment of drug resistant -TB  
Treatment of MDR-TB and XDR-TB has been challenging for both patients and healthcare 
systems worldwide. Conventional treatment regimens were of lengthy duration, approximately 
18 - 24 months. These long regimens consisted of drugs that were less potent and less effective 
than those drugs used to treat susceptible TB. Due to the use of these less potent drugs coupled 
with the length of treatment duration, treatment outcomes for drug resistant TB were generally 
poor. Studies have shown that only 54% of MDR-TB patients and 30% of XDR-TB patients 
achieve cure. Secondly, prolonged use of these drugs cause multiple severe adverse effects, 
which include permanent hearing loss, gastrointestinal intolerance and renal impairment. 
Because of difficulty in getting to healthcare facilities many patients are lost to follow up 
resulting in non-adherence and further transmission of drug resistant strains [35]. 
 
1.2.5.2 Introduction of Shortened treatment regimens for MDR-TB  
 In 2016, the WHO released an updated guideline on the management of MDR-TB. The 
guideline states that in “patients with RR-TB or MDR-TB who were not previously treated 
with second-line drugs and in whom resistance to FQ and SLIDs was excluded or considered 
highly unlikely, a shorter MDR-TB regimen of 9–12 months may be used instead of the longer 
regimens”. This recommendation was based on observational studies, which have shown 
successful patient outcomes when compared to the conventional long regimen 84% ( 95% CI 
79-87) vs 62% (95% CI 53-70) from observational studies in 10 countries [5].  
Among the ten studies that contributed to the regimen change, was the Bangladesh study 
published by Aung et al. They described 515 patients who had a success rate of 84,4% and had 
a bacteriologically favourable outcome. Their regimen comprised of high-dose gatifloxacin, 
ethambutol, pyrazinamide, and clofazimine throughout the duration, with a 4-month intensive 
phase of kanamycin, prothionamide, and INH. They observed that the strongest risk factor for 
a bacteriologically unfavourable outcome was associated with high-level gatifloxacin 
resistance [36]. Another trial performed in nine African countries also showed favourable 
outcomes in patients placed on the SR. This study showed a success rate of 82%. The regimen 
used in this study was formulated using the Bangladesh regimen; however, they used normal 
dose moxifloxacin (10-15mg/kg daily) instead of high dose gatifloxacin. They also observed 
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that the short regimen was effective in HIV positive patients but deaths were more frequent in 
this group. This study also showed that patients who had FQ resistance had an unfavourable 
outcome [37]. The STREAM trial, which included participants from South Africa, found that 
in patients with RR-TB that was susceptible to FQ and SLIDs, the shortened regimen, was 
statistically non-inferior to a long regimen in terms of efficacy (78,8 % compared to 79,8%) 
[38]. 
 In 2017, South Africa adopted the WHO short MDR-TB regimen as “Modified South African 
9-12 Month Regimen” which replaced the existing conventional regimen based on certain 
inclusion/exclusion criteria. The modified regimen comprises the intensive (injectable) phase; 
kanamycin+ moxifloxacin + clofazamine + ethionamide + pyrazinamide + high dose INH + 
ethambutol for 4-6 months followed by the continuation phase of moxifloxacin + clofazimine  
+ pyrazinamide + ethambutol for a further 5 months. There are a few concerns regarding the 
implementation of the shortened regimen (SR) in South Africa. Most countries where these 
studies were performed do not have a similar prevalence of HIV and drug resistant TB. South 
Africa’s higher prevalence of HIV and drug resistant TB may affect patient outcomes 
negatively. Secondly, the recent drug resistant survey shows high levels of drug resistance to 
ethambutol and pyrazinamide. This raises concern because these two drugs are used in the 
modified South African regimen in both intensive phase and continuation phase [6]. 
 
1.2.6 Implementation of Drug resistant TB reflex testing (DR-TB Reflex testing) in South 
Africa  
With the new treatment recommendations issued by the WHO, regarding the SR for RR-TB 
and MDR-TB treatment, the requirement for rapid methods to detect resistance to FQ and 
SLIDs became necessary to rapidly triage MDR-TB and RR-TB patients into using this 
regimen [5]. The lengthy turnaround time of DST became inadequate in the triaging process 
for patients and a more rapid, genotypic means of testing became mandatory. 
Therefore in order to facilitate the use of these regimens, the WHO published a policy guidance 
in 2016 stating, “for patients with confirmed RR-TB or MDR-TB, the SL-LPA may be used as 
the initial test, instead of phenotypic culture based DST to detect resistance to FQ and SLIDs” 
[7, 8]. These recommendations apply to the direct testing of clinical specimens regardless of 
smear status. 
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The evidence for this recommendation was based on 29 studies identified for both GenoType 
MTBDRsl Version 1 and GenoType MTBDRsl Version 2. Of these studies, only three studies 
evaluated Version 2. One study was published by Tagliani et al. and the other two were 
unpublished (FIND 2016, NICD) [7]. In view of the limited number of studies, in the 2016 
policy guidance, the WHO acknowledged that data comparing direct testing on smear negative 
and positive specimens were sparse. Tagliani et al. conducted a multicenter study on smear 
positive clinical specimens in Europe. When compared to DST, the test shows an overall 
sensitivity and specificity to be 93% and 98,3% for the FQ and 88,9% and 91,7% for the SLIDs. 
They observed that the most common FQ mutations were gyrA MUT 3C (D94G), and MUT1 
(A90V). They also observed that 17,5% of FQ resistant strains showed a mixture of WT and 
MUT strains which indicates possible heteroresistance. These strains were confirmed as 
resistant by DST thereby indicating that a resistant strain was present in the specimen. For 
SLIDs, they found that the commonest mutation was the A1401G in the rrs region. 
Heteroresistance for SLIDs was 17,5% as well and observed mainly in the rrs region  The 
limitation of this study was its inability to include smear negative specimens [39].  
The other two studies that guided the WHO recommendation showed that direct testing had a 
higher inconclusive rate on smear negative than smear positive specimens. These studies had 
a small specimen size with only 24 individuals. These studies were performed in a research 
setting where researchers reviewed thirty results only. Of these results, 6/30 (20%) showed an 
inconclusive rate of for direct testing on smear negative specimens [7].  
A Cochrane systematic review published by Theron et al. concluded that further evaluation is 
required for the use of MTBDRsl Version 2.0 on smear negative specimens in different 
geographic settings. They highlighted that there was a paucity of data regarding direct testing 
on smear negative clinical specimens by the SL-LPA, and that most studies described its 
performance directly on cultured isolates or smear positive clinical specimens. In those studies 
that did analyse SL-LPA results in smear negative specimens, the specimen size was too small 
[8].  
Gardee et al. evaluated the performance of the GenoType MTBDRsl on known clinical isolates 
from South Africa. Their study showed a sensitivity and specificity of 100% and 98,9% for FQ 
when tested against DST for ofloxacin alone and 89,2% and 98,5% for SLIDs. They also found 
that majority of FQ mutations were in the gyrA region, specifically at codon 94 and 90. The 
commonest mutations at codon 94 were MUT3C (D94G), MUT3A (D94A) and MUT3D 
(D94H). Heteroresistance for FQ was seen in 16,5% of the isolates and undefined FQ mutations 
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were observed in 9,4% of the isolates. These undefined isolates were confirmed as resistant by 
whole genome sequencing which indicated that the SL-LPA missed some mutations that are 
included in the assay and it also missed mutations that are not covered by the assay. The SL-
LPA detected MUT1 (A1401G) in the rrs gene as the commonest mutation. Similar to Tagliani 
et al., a limitation of this study was the lack of direct testing on clinical specimens and more 
specifically smear negative specimens [40].  
Another study in China evaluated the GenoType MTBDRsl by comparing SL-LPA to DST and 
sequencing. They found the sensitivity for GenoType MTBDRsl for FQ and SLIDs to be 80,5% 
and 80,7% respectively. The predominant mutation for FQ was gyrA MUT3B and MUT3C 
(D94N and D94G). Resistance to SLIDs was predominant in the rrs region, specifically 
A1401G. C1402T in the eis region was observed in 10,5% of their isolates [41]. A study in 
India also aimed to characterize mutation patterns observed by the GenoType MTBDRsl 
Version 2 in their region. They found that among newly diagnosed RR-TB patients, 25% had 
displayed resistance to FQ with a predominance of the gyrA MUTC (42%) mutation. The most 
frequent rrs mutation was A1401G [42]. 
In 2017, the NDoH took both WHO recommendations together (the use of molecular line probe 
assays and the SR) and developed a new laboratory–clinical algorithm termed the Drug 
Resistant TB Reflex Testing (DR-TB Reflex). This algorithm was implemented nationally in 
2017. In this algorithm, any patient with newly diagnosed RR-TB by GXP must have a second 
specimen sent to the laboratory for DR-TB Reflex testing.  
DR-TB Reflex testing contains a set of laboratory tests that are performed directly and 
sequentially on the same clinical specimen. These tests include: 
(i) Smear microscopy (to indicate infectiousness of the patient and for programmatic 
monitoring),  
(ii) TB culture with the BACTEC MGIT 960 system (to enable phenotypic DST),  
(iii) FL-LPA (to confirm the susceptibility pattern of rifampicin and isoniazid) followed 
sequentially by, 
(iv) SL-LPA (to determine the presence or absence of resistance to FQ and SLIDs).  
(v) DST using BACTEC MGIT 960 system on selected isolates (isolates with katG & inhA 
mutations, pre-XDR-TB and XDR-TB). 
16 
 
Since the implementation of DR-TB Reflex testing in KZN in January 2017, there have been 
no published reports on the experience of the routine use of the SL-LPA directly on clinical 
specimens within South Africa nor in KZN specifically, where the diagnosis of smear negative 
TB remains challenging. The literature is clear that data regarding the use of the GenoType 
MTBDRsl Version 2 directly on smear negative clinical specimens is sparse. Additionally, the 
performance of diagnostic tests in programmatic settings is often inferior compared to that in 
controlled research settings. Given the high burden of drug resistant TB, HIV associated TB, 
and smear negative TB in KZN; this is an ideal region to assess the feasibility of introducing 
the SL-LPA routinely in the DR-TB Reflex testing algorithm. 
 
1.3 Research questions 
In South Africa, specifically the KZN province, which is a well-known high burdened HIV and 
drug resistant TB area, what is the diagnostic yield of the GenoType MTBDRsl Version 2 when 
performed directly on clinical specimens within a programmatic setting? 
Which mutation patterns does the GenoType MTBDRsl Version 2 detect for FQ and SLIDs?  
1.4 Aims  
a) To determine the diagnostic yield of the GenoType MTBDRsl Version 2 assay when 
performed directly on clinical specimens. 
b)  To describe which mutation patterns are identified by the GenoType MTBDRsl Version 2 
assay in KZN.  
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2.1 Abstract  
Background. Since the implementation of shortened drug regimens for the management of 
drug resistant tuberculosis (TB), there is a growing need for rapid detection of resistance to 
second line antimycobacterial drugs. The GenoType MTBDRsl Version 2 allows for the 
rapid molecular detection of resistance conferring mutations to fluoroquinolones (FQ) and 
second line injectable drugs (SLIDs). Although the GenoType MTBDRsl is recommended for 
use directly on smear positive and smear negative clinical specimens, the feasibility of using 
this assay routinely within a programmatic setting in high HIV/TB endemic areas requires 
exploration. 
Objectives. To assess the feasibility of routinely using the GenoType MTBDRsl in a high 
HIV/TB prevalent region and to describe the various circulating resistance patterns detected 
by this test in KwaZulu-Natal.  
Methods.  A retrospective data analysis of all GenoType MTBDRsl results in newly 
diagnosed rifampicin resistant (RR-TB)/multidrug resistant TB (MDR-TB) specimens was 
performed. The assays performance on direct testing of smear positive and smear negative 
specimens was compared. The various mutation patterns for FQ and SLIDs identified by this 
test was observed. 
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Results. Of 1873 RR-TB/MDR-TB, 37,4% were smear negative and 62,5% was smear 
positive. In smear negative specimens, the GenoType MTBDRsl showed an inconclusive rate 
of 61,2%, whilst amongst the smear positive specimens, an inconclusive rate of only 6,6% 
was observed. The commonest mutation pattern observed for FQ occurred at the gyrA gene at 
codon 90 (A90V) 61/158(38,6%) followed by the D94G mutation 31/158 (19,6%).  
Heteroresistance for FQ was observed in the gyrA gene for 6/158 (10,1%) isolates. For 
SLIDs, the commonest mutation occurred in the rrs region specifically A1401G, 71/108 
(65,7%) followed by C1402T at 20/108 (18.5%).  
Conclusion. The routine use GenoType MTBDRsl Version 2 assay is more feasible in smear 
positive specimens as compared to smear negative specimens in high HIV/TB settings. To 
improve future development of the assay, further studies looking at the various resistance 
patterns are required. 
 
2.2 Manuscript  
2.2.1 Introduction 
Globally there has been a reduction in disease burden caused by tuberculosis (TB) however; 
TB remains the leading cause of death from a single infectious agent worldwide. In 2018, 
South Africa continued to feature on the World Health Organization (WHO) list of top 30 
high TB burden countries and it is one of the top 14 high burden countries with drug-resistant 
and HIV associated TB [1]. WHO statistics show that globally an estimated 60% of the 
incident TB cases in 2018 were HIV infected. The high HIV/TB co-infection rate contributes 
to the TB disease burden because patients with co-infection are frequently associated with 
smear negative pulmonary TB or extrapulmonary TB, which is diagnostically challenging [2-
4]. In the recent South African national drug resistant prevalence survey, the prevalence of 
multidrug resistant (MDR-TB) tuberculosis was 2,1% (95% CI 1,5–2,7) among new 
tuberculosis cases and 4,6% (3,2–6,0) among retreatment cases [5]. MDR-TB is defined as 
resistance to rifampicin and isoniazid (INH). In the survey, although the prevalence of MDR-
TB varied between all 9 provinces, KwaZulu-Natal (KZN), had amongst the highest 
prevalence of patients with MDR-TB, showing an overall estimate of 2,9% (95% CI 1,8 - 
4,5) which is higher than the national average of 2,8%.  
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Given the high MDR-TB prevalence rate and its associated poor treatment outcomes, in 
2016, the South African National Department of health (NDoH) replaced the existing long 
conventional MDR-TB treatment regimen with the “Modified South African 9-12 Month 
Regimen”. This was in accordance with the 2016 WHO shortened MDR-TB treatment 
recommendation which showed successful patient outcomes when compared to the 
conventional long regimen 84 %( 95% CI 79-87) vs 62% (95% CI 53-70) from observational 
studies in ten countries [6]. The “Modified South African 9-12 Month Regimen” comprised 
of an injectable phase; kanamycin + moxifloxacin + clofazamine + ethionamide + 
pyrazinamide + High Dose INH + ethambutol for 4-6 months, followed by the continuation 
phase of moxifloxacin + clofazamine + pyrazinamide + ethambutol for a further 5 months 
[7]. The shortened regimen (SR) is only eligible for patients with rifampicin resistant TB 
(RR-TB) and MDR-TB; therefore the NDoH adopted the 2016 WHO policy on the use 
molecular line probe assays to rapidly exclude patients with extensively drug resistant TB 
(XDR-TB) and pre-XDR-TB [7]. XDR-TB is defined as resistance to rifampicin, isoniazid, a 
fluoroquinolone (FQ) and second line injectable drugs (kanamycin, amikacin or 
capreomycin) (SLIDs). Pre-XDR-TB is defined as resistance to rifampicin, isoniazid and 
either a FQ or SLIDs [8].  
Considering both guidelines (the use of molecular line probe assays and SR), in 2017, 
nationwide implementation of a laboratory-clinical algorithm termed Drug Resistant TB (DR-
TB) Reflex testing came into effect. In this algorithm, any patient with newly diagnosed RR-
TB by GeneXpert (GXP) (Cepheid, United States) must have a second specimen sent to the 
laboratory for DR-TB Reflex testing. DR-TB Reflex testing contains a set of laboratory tests 
which includes the routine use of the GenoType MTBDRsl Version 2 line probe assay(Hain 
Lifescience, Nehran, Germany) (SL-LPA) to be performed directly on clinical specimens 
regardless of smear status [7]. The SL-LPA is a qualitative test for the identification and 
susceptibility testing of Mycobacterium tuberculosis complex (MTBC). It simultaneously 
detects resistance to FQ and SLIDs directly from smear positive and smear negative sputum 
specimens by detecting mutations in the gyrA, gyrB, rrs and eis genes respectively. This test 
can be performed on cultured isolates from all specimen types [9].  
Since the WHO recommendation for the use of SL-LPA in 2016, only a few studies have 
assessed its performance on smear negative clinical specimens. A Cochrane review published 
by Theron et al. highlighted that further evaluation is required for the use of MTBDRsl 
Version 2.0 on smear negative specimens in different geographic settings. They found that 
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most studies described its performance directly on cultured isolates or smear positive clinical 
specimens. For those studies that did analyse SL-LPA in smear negative specimens, the 
specimen size was too small [4]. Additionally, the 2016 WHO policy acknowledges the 
results generated from the SL-LPA V2 directly from smear negative specimens have a higher 
inconclusive rate than smear positive specimens [10]. The lack of data regarding direct 
testing of smear negative clinical specimens is particularly concerning in a high HIV/TB 
prevalent country, like South Africa. Studies conducted in KZN and other parts of Africa 
have confirmed that TB is often undetected among HIV-infected patients because they are 
likely to present with smear negative pulmonary TB [11, 12].  Therefore, the WHO still 
recommends that sputum culture should be encouraged as part of the diagnostic workup in 
HIV infected individuals [13]. 
Since the implementation of DR-TB Reflex testing in KZN in January 2017, there have been 
no published reports on the experience of the routine use of the SL-LPA on clinical 
specimens within South Africa nor in KZN specifically, where the incidence of smear 
negative TB remains high. The performance of diagnostic tests in programmatic settings is 
often inferior compared to that in controlled research settings. Given the high burden of drug 
resistant, TB and HIV associated TB in KZN; this is an ideal region to assess the feasibility 
of introducing the SL-LPA as part of the DR-TB reflex laboratory algorithm. Therefore, the 
objective is to evaluate the feasibility of routine use of the SL-LPA when performed directly 
on clinical specimens, as well as characterize the various mutation patterns in an area with 
high TB/HIV prevalence. This will significantly contribute to our knowledge on the routine 
use of this assay within the KZN population.  
2.2.2 Methods 
Study design 
This is retrospective observational study of laboratory results acquired from specimens 
received for DR-TB reflex testing from January – December 2018 (Figure: 1). 
Study setting 
Since implementation of DR-TB Reflex testing in 2016, for all newly diagnosed patients with 
RR-TB diagnosed by GXP, a second sputum specimen was submitted to the South African 
National Accreditation System (SANAS) accredited KZN provincial TB reference laboratory 
for DR-TB Reflex testing. Whilst awaiting results of the DR-TB reflex testing, patients were 
commenced on the SR regimen, provided they did not meet any of the exclusion criteria. 
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Exclusion criteria for the SR include: (i) History of previous second line drugs ≥ 1 month; (ii) 
Complicated extra-pulmonary TB; (iii) Both INH mutations; (iv) Contact with XDR/ Pre 
XDR pateints.   
DR-TB Reflex testing contains a set of laboratory tests which include, Auramine smear 
microscopy, TB culture on Mycobacteria Growth Indicator Tube (MGIT) 960 system 
(BACTEC MGIT Becton Dickinson, USA), GenoType MTBDRplus (FL-LPA) (Hain 
Lifescience, Nehran, Germany),  followed by GenoType MTBDRsl Version 2 sequentially on 
the same clinical specimen regardless of smear status [7]. The FL-LPA was performed to 
confirm the resistance to rifampicin (detected by GeneXpert) and test for isoniazid 
susceptibility. The SL-LPA was performed to detect susceptibility to FQ and SLIDs, which 
classified patients as MDR-TB, pre-XDR or XDR-TB. In specimens that showed 
inconclusive results for either FL-LPA or SL-LPA, the respective test was repeated on the 
corresponding cultured isolate. Once the mutations from both line probe assays were 
analysed, further phenotypic drug susceptibility testing (DST) using 1% agar proportion 
method was performed on selected isolates. These isolates included those that had double 
INH mutations (i.e. both katG and inhA mutations), pre-XDR-TB and XDR-TB. DST for 
moxifloxacin (high and low levels), capreomycin and linezolid were performed on those 
selected cultured isolates (Figure 1). 
 
 
Figure: 1. DR-TB Reflex testing algorithm. GXP: GeneXpert MTB/RIF; RIF R: rifampicin resistant; 
FL-LPA: first line-line probe assay; SL-LPA: second line-line probe assay; DST: phenotypic 
25 
 
susceptibility testing; INH: Isoniazid; XDR-TB: Extensively drug resistant TB; INH double mutation: 
both katG and inhA mutations. 
 
Laboratory Procedures 
All sputum specimens received for DR-TB Reflex testing were decontaminated using the N-
acetyl-l-cysteine sodium hydroxide (NALC-NAOH) method [14]. Thereafter 0,5ml of the 
decontaminated sputum were inoculated in BACTEC MGIT 960 tubes with PANTA 
(Polymyxin B: 6000 units; amphothericin B: 600µg; nalidixic acid: 2400µg, trimethoprim: 
600µg and azlocillin: 600µg) and loaded into the BACTEC 960 machines. From the same 
decontaminated specimen, another 10µl was removed using a sterile loop and heat fixed on 
the slide. Auramine stains were performed using the Auramine Auto-stainer [14].  
GenoType MTBDRsl Version 2 
After performing culture and smears, FL-LPA and SL-LPA were performed sequentially, 
directly on the same decontaminated specimen. The SL-LPA was performed in accordance 
with the manufacturer’s guideline. First, DNA was extracted, then amplified, followed by 
hybridization. Each strip of the assay has 27 probes, which target specific regions of gyrA, 
gyrB, rrs, and eis promoter regions in MTBC. Mutations detected in the gyrA and gyrB genes 
confer resistance to FQ, and resistance to SLIDs is detected by mutations in the rrs and eis 
genes. Interpretation of these reaction zones was in accordance to manufacturer’s guideline 
[15].  The presence of all wild type (WT) bands and no mutation (MUT) bands indicate 
susceptibility. Resistance was reported when there was absence of a WT band with presence 
of a corresponding MUT band (defined mutation), or the absence of WT bands only, without 
any corresponding MUT band (undefined mutation/resistance inferred). In certain isolates, 
where all WT probes and a MUT band developed, or multiple MUT bands developed, this 
isolate was interpreted as resistant due to heteroresistance. The SL-LPA was defined as 
uninterpretable (inconclusive) if all bands of a gene locus (including the locus control) were 
missing. In some specimens where MTBC band was present on the FL-LPA but absent on 
SL-LPA, this was reported as inconclusive.  
Data analysis 
Data of all results for both line probe assays and Auramine smears from January –December 
2018 was collected. These results were obtained from the National Health Laboratory Service 
(NHLS) laboratory information system, which contains all electronic laboratory results. 
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Duplicate specimens were removed using patients’ demographic data (name, surname and 
date of birth). Once the results were de-duplicated, all FL-LPA results that showed RR-TB 
and MDR-TB were filtered. All rifampicin susceptible and FL-LPA inconclusive results were 
excluded. (Figure: 2)  
 
Figure: 2. Flow diagram of specimens included in the study.  
 
All the RR-TB and MDR-TB results were divided into two arms according to smear status 
i.e. smear positive arm and smear negative arm. In each arm, the percentage of results that 
showed conclusive and inconclusive results by SL-LPA were calculated. From all conclusive 
SL-LPA results, the proportion was MDR-TB, pre-XDR-TB and XDR-TB were calculated. 
Once all the pre-XDR-TB and XDR-TB results were found, the original SL-LPA strips were 
read to identify which mutation pattern was detected for FQ and SLIDs. Thereafter the 
frequency at which each mutation pattern occurred was calculated.  
For de-duplication and data analysis, R software (R Core Team) was used first, and then 
exported data to Microsoft Excel (Version 2019) for further exploration.  
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2.2.3 Results  
A retrospective data analysis of GenoType MTBDRsl and corresponding smear results on 
1873 LPA MDR/Rif resistant clinical specimens over 1 year (January – December 2018) was 
performed. 
Of the 1873 clinical specimens, 37,4% (701/1873) were smear negative and 62,5%    
(1172/1873) were smear positive. Of the smear negative specimens, 67,2 % (471/701) had 
inconclusive SL-LPA results (Table 1). Of those 471 inconclusive results, in 269 results, the 
SL-LPA did not detect MTBC despite the FL-LPA showing a prominent MTBC band.  
In the smear negative arm, 32,8% (230/701) showed clear banding patterns with 77,4% 
(178/230) MDR-TB, 14,8% (34/230) pre-XDR-TB and 7,8% (18/230) XDR-TB rapidly 
diagnosed. 
For smear positive specimens, 6,6 % (77/1172) had inconclusive results. The remaining 
93,4% (1095/1172) showed clear banding patterns with 84,9% (930/1095) MDR-TB, 10,1 % 
(111/1095) pre-XDR-TB and 4,9 % (54/1095) XDR TB rapidly diagnosed.  
Overall, for MDR/Rif resistant clinical specimens, 29,3% (548/1873) had inconclusive results 
where majority of inconclusive results belonged to smear negative specimens. MTBC and its 
respective susceptibility pattern was clearly identified in 70,7% (1325/1873) of the 
specimens. In total the SL-LPA facilitated rapid diagnosis of pre-XDR and XDR in 7,7 %                                  
(145/1873) and 3.8 % ( 72/1873) respectively (Figure: 3).  
 
 
AFB Smear on MDR isolates SL-LPA Inconclusive 
n (%) 
SL-LPA 
Conclusive n (%) 
Total  
n (%) 
Negative  471 (67,2) 230 (32,8) 701 (37,4%) 
(p<0.01) 
Positive 77 (6,6) 1095 (93,4) 1172 (62,5%)  
Total Results 548  1325  1873 
Table: 1. GenoType MTBDRsl results stratified according to smear status.  
Table 1 shows GenoType MTBDRsl results stratified according to smear status. Smear negative 
specimens had significantly more inconclusive results compared to smear positive specimens (P<0.01). 
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Figure: 3. Analysis of GenoType MTBDRsl Version 2 results according to smear results. RR-TB: 
Rifampicin resistant TB; MDR TB: Multi-drug resistant TB; Smear Pos: Auramine smear positive; 
MTBC: Mycobacterium tuberculosis complex; INC: Inconclusive; XDR-TB: Extensively drug resistant 
TB; FQ: Fluoroquinolones; SLIDs: Second line injectable drugs; R: Resistant; S: Susceptible. 
Figure 3 shows that the SL-LPA did not detect the TUB band in 57.1% of inconclusive isolates. 
Amongst smear negative inconclusive results, 80,2% showed inconclusive results for both FQ and 
SLIDs.  
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Table: 2. GenoType MTBDRsl hybridization patterns observed for fluoroquinolones and second line 
injectable agents. WT: Wild type; MUT: Mutation; HR: Heteroresistance. 
Table 2 shows the commonest mutation in gyrA region was A90V and the commonest mutation for rrs 
region was A1401G 
 
When characterizing mutations, the original SL-LPA strips for all XDR (72), FQ pre-XDR      
(95) and SLID pre-XDR (50) were read. This would have resulted in 167 FQ banding 
patterns (95+72) and 122 SLID resistant patterns (72+50). Unfortunately, the banding 
patterns for 9 FQ and 14 SLID results had faded and were uninterpretable during 
retrospective analysis. Therefore, only 158 FQ mutations and 108 mutations for SLIDs were 
analysed.  
Probe Wild type Probe Mutation 
Probe 
Corresponding 
Mutation 
Total Number 
n(%)  
gyrA(n 152) 
 
WT2 Absent  No mutation Undefined  17(10.7) 
MUT 1 A90V 61 (38,6) 
MUT 2 S91P 10 (6.3) 
WT3 Absent No mutation Undefined 1(0.63) 
MUT 3A D94A 2(1.2) 
MUT 3B D94N / D94Y 13(8.2) 
MUT 3C D94G 31(19.6) 
MUT 3D D94H (rare mutation) 2(1.2) 
No WT Absent 
 
 
MUT 1 HR 4(2.5) 
MUT 3B HR 1(0.6) 
MUT 3C HR 10(6.3) 
gyrB(n=6) WT  Absent Nil Undefined 5(3.1) 
 No WT Absent  MUT 2 HR 1 (0.63) 
rrs (n=105) WT 1 Absent  MUT 1 A1401G 71(65.7) 
 MUT 2  Unknown 3 (2, 7) 
 No mutation C1402T 20(18.5) 
 WT 2 Absent No mutation  Undefined 6(5.5) 
 No WT Absent MUT 1 HR 2(1.9) 
eis(n=3) No WT Absent MUT 2 HR 3(2.8) 
 WT 1 Absent  No mutation G-37T 1 (0, 92) 
 WT2 Absent  MUT 1 C-14T 1(0, 92) 
 No mutation C-12T / G-10A 1(0, 92) 
30 
 
For the FQ, 152 mutations were observed in the gyrA region and only six mutations in the 
gyrB region. A summary of FQ and SLIDs mutations are described in Table 2. Majority of 
defined mutations occurred at codon 90 (A90V) 61/158 (38,6%) followed by the D94G 
mutation 31/158 (19,6%). Of note, 16/158 (10,1%) isolates showed heteroresistance. For the 
gyrB region, 5/6 (3,1%) mutations were undefined. Altogether, undefined FQ mutations were 
noted for 23/158 (14,5%) of the isolates.  
For SLIDs, 108 mutation patterns observed in total, 105 in the rrs region and only 3 in the eis 
region. In the rrs region the commonest mutation was rrs MUT1 (A1401G), 71/108 (65,7%) 
followed by C1402T at 20/108 (18,5%). Heteroresistance was observed in five isolates 
(4,6%).  
2.2.4 Discussion  
Following the WHO endorsement of the GenoType MTBDRsl Version 2, this test has gained 
popularity in high TB burden countries and high throughput TB laboratories to rapidly assess 
drug resistance to FQ and SLIDs. To our knowledge, since the introduction of the DR-TB 
Reflex testing clinical-laboratory algorithm in South Africa, this is the first study, which 
describes the use of this test under programmatic conditions in South Africa. In this study, the 
data analysis showed that of 1873 MDR/RR-TB, smear positive TB was predominant 
(62,5%). This percentage of smear positive TB is slightly higher when compared to another 
retrospective study performed in Western Cape, South Africa. In that study, data over a 6 
year period showed that of 36,219 cases of pulmonary TB, 19,195 (53 %) were sputum smear 
positive at the time of diagnosis [16]. However, in this study, the smear negative rate of 
37,4% is in keeping with other studies which have reported that among patients who have 
HIV/TB co-infection, sputum smear negative rates ranged from 24% to 61% [12].  
The SL-LPA performed well in the smear positive arm by showing valid and conclusive 
results for 93,4% of the specimens whilst showing inconclusive results for only 6,5% of the 
specimens. The limit of detection for SL-LPA in clinical specimens is 150 CFU/ml, therefore 
the high percentage of conclusive results is expected seeing that approximately 5000-10000 
CFU/ml of bacteria is required in smear positive sputum specimens [9]. Although smear 
positive specimens predominated, a large proportion of specimens were smear negative 
(37,4%).  In the smear negative arm, the SL-LPA showed inconclusive results in 67,1% of 
the specimens and interpretable results in 32,8% of the specimens. This high rate of 
inconclusive results in smear negative specimens is in keeping with the WHO policy 
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guidance, where they acknowledged that although data comparing direct testing on smear 
negative and positive specimens were sparse, two small studies showed that direct testing had 
a higher inconclusive rate on smear negative than smear positive specimens. These studies 
had a small specimen size with only 24 individuals. Additionally, these studies were 
performed in a research setting where researchers reviewed thirty results only, and of these 
results, 6/30 (20%) showed an inconclusive rate of for direct testing on smear negative 
specimens [10].  
Although there are no published reports from South Africa regarding the routine use of 
GenoType MTBDRsl Version 2 in a programmatic setting, in the recent Rifampicin resistant 
clinical guideline released by the NDoH, the DR-TB Reflex testing laboratory algorithm was 
revised based on experience from high throughput laboratories. This guideline now 
recommends, for smear negative specimens the FL-LPA is performed routinely but SL-LPA 
will only be performed on smear positive or culture positive specimens [8]. 
Furthermore, this study found that among the smear negative inconclusive results, where the 
FL-LPA detected MTBC, the sequential SL-LPA failed to detect MTBC in 57,1% (269/471) 
of isolates. This is an unexpected finding seeing that the same DNA extraction kit is used for 
both tests. There are no reports thus far comparing the sequential testing of FL-LPA and SL-
LPA, however, Tomassicchio et al. performed a study, in which they used a similar 
sequential approach to diagnosing MDR, pre-XDR and XDR TB using GenoType MTBDRsl 
Version 1. In their study, they found that the GenoType MTBDRsl Version 1 showed a lower 
overall sensitivity in detecting MTBC and associated resistance when compared to GenoType 
MTBDRplus Version 1 for both smear positive and smear negative specimens [17].  
The performance characteristics of the MTBDRsl Version 2 has been assessed in only a few 
studies. Tagliani et al. conducted a multicentre study on smear positive clinical specimens in 
Europe. When compared to DST, the test showed an overall sensitivity and specificity to be 
93% and 98,3% for the FQ and 88,9% and 91,7% for the SLIDs. However, this study did not 
include any smear negative specimens [18]. Gardee et al. evaluated the performance of the 
GenoType MTBDRsl Version 2 by comparing it to phenotypic susceptibility testing on 
known clinical isolates from South Africa. Their study showed a sensitivity and specificity of 
100% and 98,9% for FQ when tested against ofloxacin alone and 89,2% and 98,5% for 
SLIDs. The limitation of this study was the lack of direct testing on clinical specimens and 
more specifically smear negative specimens [19]. Similarly, Yadav et al. studied the 
diagnostic accuracy of the GenoType MTBDRsl. In their study, the SL-LPA showed a high 
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sensitivity and specificity when compared to DST for levofloxacin 97, 2% (95% CI 93,5 – 
99,1) and 99,1% (95%CI 97-99,9) respectively. The sensitivity and specificity for kanamycin 
was 92,5% (95% CI 79,6 -98,4) and 99,5% (95%CI 98,1-99,9). However, a limitation in their 
study was the lack of direct testing on smear negative specimens as well [20].  
In this study, the SL-LPA enabled rapid and accurate diagnosis of 1108 (59%) cases of 
MDR/Rif resistant TB, 145 (7,7%) cases of Pre-XDR TB and 72 (3,8%)cases of XDR TB 
overall. This enabled clinicians to rapidly triage patients into their respective drug resistant 
treatment regimens. Interestingly, among all pre-XDR isolates, (taking both arms together), 
more specimens showed FQ resistance as compared to resistance to SLIDs (65,5% vs 34,5%). 
Similarly, this higher frequency of FQ resistance was reported in another study in India [21]. 
In the KZN setting, seeing that these were all newly diagnosed patients, this is of particular 
concern because it highlights the possibility of primary transmission of drug resistant TB 
strains, which has been described in recent studies in South Africa, specifically KZN [22].  
FQ resistant strains could also be a result of widespread use of FQ for other infectious 
diseases [22]. Furthermore, when it comes to the use of the shortened MDR-TB drug 
regimen, one study showed that FQ resistance was a key factor for a bacteriologically 
unfavourable outcome [23]. The latest drug resistant prevalence survey shows an estimated 
resistance of 1,2% (95% CI 2,2 -3,6) to ofloxacin in new cases and 1,5 % (95 CI 3,8 -6,7) in 
retreatment cases [5]. Future studies in South Africa assessing the frequency of FQ resistance 
is important especially since FQ have been introduced as the backbone of the new shortened 
MDR-TB treatment regimen.  
The most frequent mutations associated with FQ occurred in the gyrA region with 38,6% at 
codon 90 (A90V) and 30,3% at codon 94 (D94G, D94N/D94Y, D94A, D94H). This differs 
slightly with other published data from South Africa, India and China where studies have 
shown a predominance of mutations occurring at codon 94 and 90 respectively [19, 20, 24]. 
In comparison with Gardee et al., this study reported a comparable frequency of S91P (6,3%) 
mutations when compared to their finding of 9,8%, however the rare in silico D94H mutation 
was considerably lower (1,2% vs 10,6%) [19]. Regarding resistance to SLIDs, the 
predominant mutation was rrs MUT1 (A1401G) 71 (65,7%) followed by C1402T 20 
(18,5%). This was consistent with other published data [18, 19]. Only 3/108 specimens 
displayed resistance in the eis promoter region. The intention of the improved version of this 
test was to increase detection of resistance by the addition of the gyrB and eis genes; 
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however, this study indicates that mutations in the gyrB and eis promoter regions only 
contributed to approximately only 4% of resistance.  
Heteroresistance occurs when there is co-existence of susceptible and resistant TB strains in 
the same specimen. It can be due to transmission of an infection with two different strains, or 
the development of resistance in patients with susceptible TB that were inadequately treated. 
This study showed that heteroresistance was noted with both FQ and SLIDs however, it was 
more predominant for FQ in the gyrA region 16/158 (10,5%). All these heteroresistant strains 
were identified by the presence of all WT bands plus a positive MUT band. These specimens 
were reported as resistant, however the clinical relevance of these heteroresistant specimens 
are largely unknown. Gardee et al. observed FQ heteroresistance in 16,5% of ofloxacin 
resistant strains [19]. Heteroresistance is not unexpected in high TB/HIV endemic areas 
where high transmission rates may occur. A study conducted by Warren et al. in Cape Town 
South Africa showed that multiple infections are not infrequent, due to high rate of re-
infection in a high incidence setting [25]. 
For undefined mutations, resistance was inferred for both FQ and SLIDs. The majority of 
these mutations were seen in the gyrA region, specifically with an absent WT2 and no MUT 
bands appearing 17/158 (10,7%). Undefined gyrA mutations were further explored in another 
South African study. In that study, resistance was confirmed by DST and whole genome 
sequencing [18].  This highlights the limitation of the SL-LPA whereby the mutation causing 
resistance, is not covered by the mutation probes included in the assay [9, 19]. In these 
undefined mutations, whole genome sequencing may be beneficial to inform the mutations 
that are circulating within South Africa. Whole genome sequencing may also contribute to 
our knowledge on the clinical significance of these undefined mutations, as well as inform 
the design of future molecular tests.    
A limitation in this study was that we did not compare and confirm the resistance patterns 
detected by the GenoType MTBDRsl results with DST. This was either due to contamination 
of several cultured isolates or no growth from clinical specimens. Secondly, we did not 
confirm undefined mutations with DST or WGS. Another limitation is that the mutation 
profile for the isolates studied belonged to one province only and did not include other areas 
within the country. 
In conclusion, the GenoType MTBDRsl Version 2 is a valuable assay for the rapid and early 
diagnosis of pre-XDR and XDR-TB directly from smear positive specimens. However, when 
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performed directly on smear negative specimens, the inconclusive rate is much higher. In this 
study, based on the poor performance of the GenoType MTBDRsl on smear negative 
samples, it is recommended that, the SL-LPA should be performed on smear positive clinical 
specimens only. For smear negative specimens, the SL-LPA should be performed on the 
positive cultured isolates only in order to increase the rate of conclusive results. The clinical 
implications of this will be a longer turnaround time (TAT) when compared to processing 
directly on the clinical specimens. Despite the longer TAT, these patients should be 
commenced on SR as smear negative pre-XDR and XDR-TB only constitute a small amount 
(2.8%) among RR cases in this study. Further studies looking at the diagnostic accuracy in 
smear negative specimens in different geographic settings are required. In view of the revised 
NDoH treatment guideline where injectable free regimen is now recommended, rapid 
diagnostic tests require updating because the clinical significance of mutation patterns in 
SLIDs is now questionable.  
Furthermore, more studies looking at the various patterns of resistance in different 
geographic areas is required. This will inform future development of the test to include 
relevant mutation probes thereby improving the overall detection of resistance.  
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Figure: 1. DR-TB Reflex testing algorithm. GXP: GeneXpert MTB/RIF; RIF R: rifampicin resistant; 
FL-LPA: first line-line probe assay; SL-LPA: second line-line probe assay; DST: phenotypic 
susceptibility testing; INH: Isoniazid; XDR-TB: Extensively drug resistant TB 
 
Figure: 2. Flow diagram of specimens included in the study.  
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Figure: 3. Analysis of GenoType MTBDRsl Version 2 results according to smear results. RR-TB: 
Rifampicin resistant TB; MDR TB: Multi-drug resistant TB; Smear Pos: Auramine smear positive; 
MTBC: Mycobacterium tuberculosis complex; INC: Inconclusive; XDR-TB: Extensively drug 
resistant TB; FQ: Fluoroquinolones; SLIDs: Second line injectable drugs; R: Resistant; S: 
Susceptible. 
 
 
AFB Smear on MDR isolates SL-LPA Inconclusive 
n (%) 
SL-LPA Conclusive 
n (%) 
Total  
n (%) 
Negative  471(67,2) 230(32,8) 701(37,4%) 
Positive 77(6,6) 1095(93,4) 1172(62,5%)  
Total Results 548  1325  1873 
Table: 1. GenoType MTBDRsl results stratified according to smear status.  
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Probe Wild type Probe Mutation Probe Corresponding 
Mutation 
Total Number 
n(%)  
gyrA(n 152) 
 
WT2 Absent  No mutation Undefined  17(10.7) 
MUT 1 A90V 61 (38,6) 
MUT 2 S91P 10 (6.3) 
WT3 Absent No mutation Undefined 1(0.63) 
MUT 3A D94A 2(1.2) 
MUT 3B D94N / D94Y 13(8.2) 
MUT 3C D94G 31(19.6) 
MUT 3D D94H (rare mutation) 2(1.2) 
No WT Absent 
 
 
MUT 1 HR 4(2.5) 
MUT 3B HR 1(0.6) 
MUT 3C HR 10(6.3) 
gyrB(n=6) WT  Absent Nil Undefined 5(3.1) 
 No WT Absent  MUT 2 HR 1 (0.63) 
rrs (n=105) WT 1 Absent  MUT 1 A1401G 71(65.7) 
 MUT 2  Unknown 3 (2, 7) 
 No mutation C1402T 20(18.5) 
 WT 2 Absent No mutation  Undefined 6(5.5) 
 No WT Absent MUT 1 HR 2(1.9) 
eis(n=3) No WT Absent MUT 2 HR 3(2.8) 
 WT 1 Absent  No mutation G-37T 1 (0, 92) 
 WT2 Absent  MUT 1 C-14T 1(0, 92) 
 No mutation C-12T / G-10A 1(0, 92) 
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Table: 2. GenoType MTBDRsl hybridisation patterns observed for fluoroquinolones and second line 
injectable agents. WT: Wild type; MUT: Mutation; HR: Heteroresistance. 
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Mmed Protocol Final BREC submission 
Principal Investigator: Dr. Keeren Lutchminarain (MBBcH –Wits; FCPath Microbiology)  
Project Title: Feasibility of routine use of the Genotype MTBDRsl Version 2 assay as part of 
the Drug resistant TB Reflex Testing (DR-TB) algorithm within the Kwazulu Natal (KZN) 
central TB laboratory  
Background Literature Review and Introduction 
Globally there has been a reduction in disease burden caused by tuberculosis (TB) however; 
TB remains the leading cause of death from a single infectious agent worldwide. In 2017, an 
estimated 10.0 million people developed TB disease of which two thirds belonged to eight 
countries namely India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and 
South Africa. Furthermore, multidrug resistant TB (MDR-TB), a global health crisis, continues 
to pose a challenge. An estimated 558,000 people developed TB resistant to rifampicin (RR-
TB) in 2017 of which approximately 82% had multidrug resistant TB (MDR-TB) [1].  
In 2018, South Africa continued to feature on the WHO list of top 30 high TB burden 
countries. Additionally, it is one of the top 14 high burden countries with drug-resistant and 
HIV associated TB [1]. In the most recent national drug resistant prevalence survey, the 
prevalence of MDR tuberculosis was 2.1% (95% CI 1·5–2·7) among new tuberculosis cases 
and 4.6% (3·2–6·0) among retreatment cases. The prevalence of MDR TB has varied 
between all 9 provinces, however, the province of KwaZulu-Natal(KZN),has amongst the 
highest prevalence of patients with MDR-TB, showing an overall MDR estimate of 2.9% 
(95%CI 1.8 -4.5) which comes in higher than the national average of 2.8% [43]. In 2012, 
there were 6630 new cases of laboratory confirmed MDR TB and 754 cases of laboratory 
confirmed extensively drug resistant TB (XDR-TB) cases, making KZN the province with the 
highest MDR and XDR TB burden in South Africa at the time[44]. 
Historically, within South Africa, laboratory diagnosis of TB relied on smear microscopy and 
subsequent culture on liquid or solid media in selected cases. Conventional culture based 
drug susceptibility testing (DST) was primarily used to confirm MDR and XDR TB. The 
traditional method of initial TB diagnosis using smear microscopy has several limitations, the 
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most important being a lack of sensitivity[27]. Reported sensitivities of the improved Light 
Emitting Diode(LED) microscopy are between 70 and 78% [45, 46].The sensitivity of smear 
microscopy is further reduced by approximately 15% in patients with HIV co-infection [4]. 
This reduction in sensitivity within the South African population gave rise to a further 
diagnostic challenge in view of the high HIV/TB co-infection rate where a considerable 
number of patients have smear negative TB.  The most recent WHO statistics shows that an 
estimated 60% of the incident TB cases in 2018 were HIV infected [1] .  
Due to this high prevalence of TB, TB/HIV co-infection and drug resistant TB in SA, it became 
increasingly important to implement rapid genotypic methods for detection of TB and 
rifampicin resistance at the time of initial patient presentation[27].  Therefore,  in 2011, 
following the World Health Organization strong recommendation for the use of Xpert, 
endorsing it as ‘‘the initial diagnostic test in individuals suspected of MDR-TB or HIV 
associated TB’’, the South African Department of Health(NDoH) together with National 
Health Laboratory Services(NHLS), rolled out the use of GeneXpert nationwide[28].The 
GeneXpert MTB/RIF assay proved superior to smear microscopy for initial diagnosis of MTB. 
This is largely because of its ability to diagnose MTB and detect Rifampicin resistance on 
unprocessed clinical specimens, using real time PCR technology. The low limit of detection 
of 131 CFU/ml greatly improved the sensitivity of the assay and contributed to higher 
sensitivity than that of smear microscopy. Laboratory evaluations of the GeneXpert MTB/RIF 
assay showed a sensitivity of 98.3% on smear positive cases [30].  
Although the GeneXpert MTB Rif Assay may lead to more TB diagnoses, the introduction of 
this molecular technique still posed a challenge in our patient population due to its limited 
sensitivity of 66.1% (95%CI ,56.4,74.9) in patients with smear negative TB[32]. The 
GeneXpert MTB Ultra was designed to improve the sensitivity of the assay in smear negative 
TB to 78.9 %( 95%CI, 70.0, 86.1), however a considerable gap in sensitivity remains when 
compared to its performance in smear positive clinical specimens[32]. As a result, the NDoH 
uses a specific algorithmic approach for the use of GeneXpert in HIV positive patients. In this 
patient population, a negative GeneXpert result cannot adequately rule out TB and a 
subsequent specimen for culture confirmation of viable bacilli must be obtained. Thereafter, 
if TB was cultured, further molecular testing using Genotype MTBDRplus is used for the 
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confirmation of rifampicin and isoniazid susceptibility. In RR-TB and MDR-TB cases further 
drug susceptibility testing (DST)for second line drugs is required.[33]  
Traditionally in South Africa, phenotypic DST for second line drugs was performed on liquid 
and solid media using the BACTEC MGIT 960 Automated mycobacterial detection system 
(BD Biosciences Becton, Dickinson and Company; USA) and the agar proportion method 
respectively. With the new recommendations issued by the WHO, regarding a shortened 
regimen (SR) for MDR-TB treatment, the requirement for rapid second line DST for 
fluoroquinolones (FQ) and second line injectable drugs(SLID) became necessary to rapidly 
triage  MDR and RR-TB patients who could benefit from the SR , into using this regimen[5]. 
The lengthy turnaround time of phenotypic DST became inadequate in the triaging process 
for patients and a more rapid, genotypic means of testing became mandatory[6].  
In 2015, Hain Lifescience released a new version of the Genotype MTBDRsl line probe assay 
Version 2 (SL LPA V2) (Hain Lifescience, Nehran, Germany). This assay offers rapid detection 
of pre-XDR and XDR TB. The GenoType MTBDRsl VER 2.0 (SL LPA V2) is a qualitative test for 
the identification of MTB and its resistance to FQ and SLID from smear-positive or smear 
negative sputum specimens and cultured isolates. The genetic targets included in this assay 
are gyrA and gyrB for FQ and the rrs and eis promoter for SLID[34]. Following a Cochrane 
systematic review, the WHO published a new recommendation in 2016 stating, for patients 
with confirmed RR-TB or MDR-TB, the Genotype MTBDRsl may be used as the initial test, 
instead of phenotypic culture based DST to detect resistance to FLQ and SLID[7, 8]. There 
are only a few studies to assess the performance characteristics of the MTBDRsl Version 2. 
Tagliani et al. conducted a multicenter study on smear positive clinical specimens in Europe. 
When compared to phenotypic susceptibility testing, the test shows an overall sensitivity 
and specificity to be 93% and 98.3% for the FLQ and 88.9% and 91.7% for the SLID. 
However, this study was limited in its ability to include smear negative specimens[39]. 
Gardee et al. evaluated the performance of the Genotype MTBDRsl on known clinical 
isolates from South Africa. Their study showed a sensitivity and specificity of 100% and 
98.9% for FQ when tested against ofloxacin alone and 89.2% and 98.5% for SLID. Here again, 
a limitation of the study was the lack of direct testing on clinical specimens and more 
specifically smear negative specimens.[40] Additionally, studies published in the 2016 WHO 
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policy acknowledges that the results generated from the SL LPA V2 directly from smear 
negative specimens have a higher inconclusive rate than smear positive specimens[7].   
Taking both the shortened MDR treatment and the use of the SL LPA V2 WHO 
recommendations into consideration, the NDoH and together with relevant stakeholders 
incorporated these recommendations into clinical practice by developing a revised 
laboratory – clinical algorithm. South Africa adopted the WHO short MDR-TB regimen as 
“Modified South African 9-12 Month Regimen” which replaced the existing conventional 
regimen based on certain inclusion/exclusion criteria. The modified regimen comprises the 
intensive (injectable) phase; Kanamycin (Km) + Moxifloxacin (Mfx) + Clofazamine (Cfz) + 
Ethionamide (Eto) +Pyrazinamide (Z) + High Dose Isoniazid (Hh) + Ethambutol (E)   for 4-6 
months followed by the continuation phase of Mfx + Cfz  + Z + E for a further 5 months. In 
order for the successful triage of RR-TB and MDR TB patients, the mutation patterns for INH, 
Mfx and Km must be known so treatment can be tailored accordingly. The simultaneous 
national roll out of the SL LPA V2 grants the laboratory and the clinicians knowledge of these 
mutations.  Together with the use of the SR and the roll out of the Genotype MTBDRsl 
Version 2, a new laboratory – clinical algorithm termed the Drug Resistant TB Reflex Testing 
(DR-TB Reflex) was implemented nationally mid-2016. Part of this algorithm includes the use 
of Genotype MTBDRplus followed by Genotype MTBDRsl sequentially on clinical specimens 
regardless of smear status [6].  
Since the implementation of DR-TB Reflex testing in KZN in January 2017, there have been 
no published reports on the experience of the routine use of the SL LPA V2 on clinical 
specimens within South Africa nor in KZN specifically, where the incidence of smear 
negative TB remains high. The performance of diagnostic tests in programmatic settings is 
often inferior compared to that in controlled research settings. Given the high burden of 
drug resistant TB and HIV associated TB in KZN, this is an ideal region to assess the feasibility 
of introducing the SL LPA V2 in the DR-TB reflex algorithm. Therefore, evaluating the 
performance of the SL LPA V2 in the DR-TB reflex algorithm, in an area with high TB/HIV 
prevalence, will significantly contribute to our knowledge as to how feasible the routine use 
of this assay is within our population.  
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Aim of the research project 
The overall goal of this research project is to assess the feasibility of routine use of the SL 
LPA V2 in DR-TB Reflex testing within the KZN central TB laboratory, where a fair proportion 
of smear negative cases of TB are observed.  
The objective of this research is to describe the experience of the routine use of the SL LPA 
V2 within the DR-TB Reflex testing algorithm in the KZN central TB culture laboratory by 
looking at: 
1)  The yield of MTBDRsl when used directly on smear positive compared to smear 
negative clinical specimens.  
2) Describe the mutation patterns detected by the MTBDRsl V2. 
3) Describing how often partially inconclusive results were observed. 
 
Methods  
Study design 
The study is a retrospective observational study using laboratory data for January – 
December 2018.  
Study setting 
In all newly diagnosed adults and children with RR-TB diagnosed by GXP, a second sputum 
specimen is submitted to the SANAS accredited provincial TB reference laboratory for DR-TB 
Reflex testing. This testing comprises a “super-set” of tests, which include smear 
microscopy, TB culture, both Genotype MTBDRplus(FL LPA) and Genotype MTBDRsl(SL LPA 
V2) line probe assays, as well as phenotypic susceptibility testing, using agar proportion 
method, in selected isolates where resistance is detected on both LPA results. Both line 
probe assays are performed irrespective of smear status. The first line LPA is performed to 
confirm the resistance to Rifampicin and test for Isoniazid susceptibility. The second line LPA 
is performed to detect mutations in FQ and SLID, which classifies patients as pre-XDR or XDR 
TB. Once the mutations from both line probe assays are analyzed, further phenotypic DST 
using agar proportion method is performed on all isolates showing double INH mutations 
(i.e. katG and inhA), all pre-XDR and XDR isolates. Phenotypic DST for Ofloxacin, 
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Moxifloxacin (high and low levels), Capreomycin and Kanamycin were performed on those 
selected cultured isolates.   
Laboratory Procedures 
Smear microscopy: is performed using the Auramine O staining method and in accordance 
with the standard operating procedure.  
TB Culture: MTB isolation from clinical specimens is performed routinely using the 
automated BACTEC mycobacteria growth indication tubes (MGIT). 
DNA Extraction: DNA was extracted from clinical specimens using a commercially available 
kit, Genolyse (Hain Lifescience) and was used in accordance to the manufacturer’s guideline  
Genotype MTBDRsl assay: Amplification and hybridization of DNA extracted from clinical 
specimens were performed according to the manufacturer’s guideline.  
DST: Phenotypic susceptibility testing was performed using 1% agar proportion method on 
Middlebrook Media (7H10) for FQ (Ofloxacin and Moxifloxacin) and SLID (Kanamycin and 
Capreomycin). 
Data collection  
Collection of all test results will be obtained from the laboratory information system (LIS) 
which contains all electronic laboratory results. 
Data analysis 
Data analysis will be performed using Microsoft Excel and Epi Info software. 
Ethical consideration 
No patient data and no consent, routine data analysis 
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